Meet Ken Aldrich the co-founder of International Stem Cell Corporation

Welcome to this podcast. I am Ken Aldrich, Chairman and co-founder of International Stem Cell Corporation. International Stem Cell Corporation recently announced that our scientific team, led by our Chief Scientist, Dr. Elena Revazova, has created a new class of human stem cell lines that do not involve the use of fertilized eggs and may enable hundreds of millions of people of different sex, ages and racial groups to benefit from cell based therapy with cells that will not be rejected by the patients own immune system after transplanting. The article was published in the on line edition of the well known peer-review publication, Cloning and Stem Cells on December 19, 2007 Since that time, we at International Stem Cell Corporation have received many questions about this discovery, most of which revolve around two basic questions: how are these cells different from what already exists and why does it matter? Since we are a public company that trades on the Bulletin Board–our symbol for those who are curious is ISCO.OB–a great deal of information about these questions has already been filed with the SEC and also been posted to our website, but I think a summary will be helpful, particular for those unfamiliar with the science of therapeutic cell implantation. The 20th Century saw the development of whole organ transplants as a means to treat injury or diseases affecting the heart, liver, kidneys and other organs. The 21st Century has already seen the beginnings of a newer a...
Source: International Stem Cell Corporation - Category: Stem Cells Authors: Tags: biotechnology science health medicine Source Type: podcasts